Tirzepatide lowered hsCRP and NT-proBNP in a meta-analysis of seven studies

The study

This is a systematic review and meta-analysis published in The Journal of Clinical Endocrinology and Metabolism. It was registered in PROSPERO (CRD42026137255). The authors searched PubMed, Embase, CENTRAL, Web of Science and Scopus from inception to April 17, 2026.

They included randomised controlled trials and prospective observational studies of tirzepatide compared with placebo or standard of care. The outcomes were NT-proBNP, high-sensitivity C-reactive protein (hsCRP), the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), the 6-minute walk test (6 MWT) and renal outcomes. Data were pooled with random-effects models using the Hartung-Knapp-Sidik-Jonkman adjustment.

Seven studies were included: 5 randomised trials and 2 observational studies, with 5406 participants in total.

What they found

• hsCRP: tirzepatide reduced it by 34.3% (95% CI: -38.4% to -30.1%; P < .0001; I2 = 0.0%; 6 studies).
• NT-proBNP: tirzepatide reduced it by 17.6% (95% CI: -26.7% to -8.5%; P = .0001; I2 = 58.1%; 3 studies).
• Function in the SUMMIT trial: KCCQ-CSS improved by 5.1 points (P < .001). The 6 MWT distance rose by 15.8 m (P = .004).
• Kidney outcomes, single-trial data: eGFR preservation was reported, at +2.90 mL/min/1.73 m2/year (95% CI: 0.94 to 4.86). Urine albumin-to-creatinine ratio fell (-25.0%; 95% CI: -36.0% to -13.0%).

The authors concluded that tirzepatide produces consistent anti-inflammatory effects and significant natriuretic peptide reductions. They rated the certainty as moderate on the GRADE system.

How much weight to give it

The hsCRP result is consistent across studies (I2 = 0.0%). The NT-proBNP result rests on only 3 studies, and its I2 of 58.1% suggests the studies differed from one another. The authors called the certainty for these two biomarkers moderate. Readers should still treat the NT-proBNP finding with some caution because of the small number of studies and the wide confidence interval.

Both hsCRP and NT-proBNP are surrogate markers. The abstract does not report heart failure hospitalisation, death or other hard outcomes. Pooling randomised and observational studies also needs care, because observational data show association, not cause. The abstract does not say which studies fed each analysis, nor does it report funding, follow-up length or tirzepatide doses.

The functional and kidney results come from single trials. The authors themselves call these hypothesis-generating and say larger dedicated heart failure trials are needed. They should not be read as pooled evidence.

For your clinic

These findings suggest tirzepatide may lower inflammatory and cardiac stress markers in people with heart failure. They do not show that it improves survival or reduces hospital admissions. They are not a basis for changing individual treatment.

If you manage patients with heart failure and obesity or type 2 diabetes, read the full paper first. Check which studies were pooled, what populations they enrolled and how the observational studies were handled. Check current guidelines before changing practice. Kidney and functional benefits are best seen as signals that still need confirmation.